Skip to main content

Ceribell, Inc.

corporate_fare Company Profile

Ceribell, Inc.

CBLL·NASDAQ·Industrial Applications And Services·CIK 0001861107

Ceribell, Inc. is a medical technology company that develops the Ceribell System, a point-of-care EEG platform. This system is designed to diagnose and manage patients with serious neurological conditions, particularly in acute care settings. The Ceribell System combines portable, rapidly deployable hardware with artificial intelligence (AI)-powered algorithms to enable quick diagnosis and continuous monitoring. The company's initial focus is on detecting and managing seizures in acute care, aiming to address limitations of conventional EEG systems that lead to diagnostic delays and suboptimal patient care. By making EEG more accessible and enabling continuous monitoring via AI, the Ceribell System assists clinicians in diagnosing and managing patients at risk of seizure. As of December 31, 2025, the Ceribell System has been adopted by more than 600 hospitals, including academic centers and community hospitals. Seizures are abnormal bursts of electrical activity in the brain, which can lead to permanent disability or death if untreated. While often linked to epilepsy, seizures in acute care can also be triggered by conditions such as brain tumors, traumatic brain injury, stroke, cardiac arrest, and sepsis.

Ceribell, Inc. (NASDAQ:CBLL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 14 items for CBLL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for CBLL spans 10-Q, 8-K, 144, 10-K.

Recent high-impact activity:

  • Ceribell 10-Q Details Q3: Revenue $29.3M, Loss Widens to $21.4M, Cash $117.5M
  • Ceribell Tops $29.3M Revenue, Lifts 2026 Guidance to $115M-$117M
  • Ceribell Launches First FDA-Cleared Delirium Monitor With $2,171 CMS Add-On Payment
  • Ceribell Q2 Revenue Beats, Guidance Raised; New Credit Facility and FDA Clearances Disclosed
  • Ceribell Tops Q2 Revenue, Lifts Full-Year Outlook, and Locks In $60M Credit Facility

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$89.06M
Net Income
-$53.41M
Diluted EPS
-$1.46
Op. Cash Flow
-$40.81M
Free Cash Flow
-$41.58M
Gross Profit
$78.27M
Operating Income
-$58.4M
Cash & Equivalents
$40.48M
Debt / Equity
0.00×
Net Margin
-60.0%
Shares Outstanding
37.49M sh
Source: 10-K · filed 2026-02-24 · accession 0001193125-26-067238

Short Interest & Short Volume

3.55 days to cover

FINRA reported short interest of 1,956,647 shares in CBLL as of the October 30, 2026 settlement, a 9.2% decrease from the prior period — about 3.5 days to cover at its recent average daily volume. On November 19, 2026, 64.8% of CBLL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,956,647 shares as of October 30, 2026
Change vs prior period▼ 9.2%
Days to cover3.55 at avg daily volume of 550,613
Daily short volume (FINRA facilities)64.8% of 124,945 shares on November 19, 2026
5-day average short volume66.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$24
52-week range · as of 2026-11-03 $10.85 – $28.89
Market cap
$1.08B
Volume
664K (1.5× avg)
3-mo avg 446.7K
From SEC filing · 2026-11-03

show_chartPrice Chart

Loading chart...

feed CBLL - Latest Insights

CBLL
Nov 03, 2026, 4:50 PM EST
Filing Type: 10-Q
Importance Score:
8
CBLL
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
CBLL
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
CBLL
Aug 10, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
CBLL
Aug 10, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
8
CBLL
Aug 10, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
8
CBLL
Jul 07, 2026, 10:01 AM EDT
Filing Type: 144
Importance Score:
7
CBLL
May 11, 2026, 4:49 PM EDT
Filing Type: 10-Q
Importance Score:
7
CBLL
May 11, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
CBLL
May 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
CBLL
Mar 03, 2026, 1:46 PM EST
Filing Type: 144
Importance Score:
7
CBLL
Feb 24, 2026, 4:36 PM EST
Filing Type: 10-K
Importance Score:
8
CBLL
Feb 24, 2026, 4:23 PM EST
Filing Type: 8-K
Importance Score:
8
CBLL
Jan 05, 2026, 10:54 AM EST
Filing Type: 8-K
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets